ZA201408769B - Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent. - Google Patents

Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent.

Info

Publication number
ZA201408769B
ZA201408769B ZA2014/08769A ZA201408769A ZA201408769B ZA 201408769 B ZA201408769 B ZA 201408769B ZA 2014/08769 A ZA2014/08769 A ZA 2014/08769A ZA 201408769 A ZA201408769 A ZA 201408769A ZA 201408769 B ZA201408769 B ZA 201408769B
Authority
ZA
South Africa
Prior art keywords
agent
prophylactic
neuropathic pain
therapeutic treatment
pain caused
Prior art date
Application number
ZA2014/08769A
Other languages
English (en)
Inventor
Hideaki Suzuki
Atsufumi Kawabata
Original Assignee
Asahi Kasei Pharma Corp
Univ Kinki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp, Univ Kinki filed Critical Asahi Kasei Pharma Corp
Publication of ZA201408769B publication Critical patent/ZA201408769B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/366Thrombomodulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/7455Thrombomodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2014/08769A 2012-05-31 2014-11-28 Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent. ZA201408769B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012125316 2012-05-31
PCT/JP2013/063743 WO2013179910A1 (ja) 2012-05-31 2013-05-17 抗癌剤に起因する末梢性神経障害性疼痛の予防及び/又は治療剤

Publications (1)

Publication Number Publication Date
ZA201408769B true ZA201408769B (en) 2015-12-23

Family

ID=49673113

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/08769A ZA201408769B (en) 2012-05-31 2014-11-28 Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent.

Country Status (20)

Country Link
US (1) US10709767B2 (en:Method)
EP (1) EP2857037B1 (en:Method)
JP (3) JP6124417B2 (en:Method)
KR (1) KR101672114B1 (en:Method)
CN (1) CN104394885B (en:Method)
AU (1) AU2013268725B2 (en:Method)
BR (1) BR112014028852A2 (en:Method)
CA (1) CA2875069C (en:Method)
DK (1) DK2857037T3 (en:Method)
ES (1) ES2743767T3 (en:Method)
HU (1) HUE045997T2 (en:Method)
IL (1) IL235984B (en:Method)
IN (1) IN2014DN10075A (en:Method)
MX (1) MX364934B (en:Method)
NZ (1) NZ702242A (en:Method)
PL (1) PL2857037T3 (en:Method)
PT (1) PT2857037T (en:Method)
RU (1) RU2595857C2 (en:Method)
WO (1) WO2013179910A1 (en:Method)
ZA (1) ZA201408769B (en:Method)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN10075A (en:Method) 2012-05-31 2015-08-21 Univ Kinki
JP6325036B2 (ja) * 2016-08-19 2018-05-16 株式会社明治 抗がん剤に起因する末梢神経障害を改善するための組成物
WO2018181860A1 (ja) * 2017-03-31 2018-10-04 東レ株式会社 末梢神経障害の治療剤又は予防剤
WO2019123144A1 (en) * 2017-12-19 2019-06-27 Synergia Life Sciences Pvt. Ltd. Vitamin k2 compositions for the treatment of drug induced neuropathy
US11497795B2 (en) * 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
MX2021003288A (es) * 2018-09-28 2021-05-13 Asahi Kasei Pharma Corp Medicacion para aliviar los sintomas de la neuropatia periferica causada por farmacos anticancerigenos y/o suprimir el inicio de la neuropatia periferica.
RU2707954C1 (ru) * 2019-01-24 2019-12-02 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения онкологической боли

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0312598B1 (en) 1987-01-08 1999-05-26 Asahi Kasei Kogyo Kabushiki Kaisha Peptide functioning to accelerate activation of protein c with thrombin
JP2738428B2 (ja) 1987-01-08 1998-04-08 旭化成工業株式会社 トロンビンによるプロテインcの活性化を促進する作用を有するペプチド
DE3876124T2 (de) 1987-04-01 1993-05-06 Mitsubishi Gas Chemical Co Immunoassay fuer thrombomodulin.
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
JPS6445398A (en) 1987-08-13 1989-02-17 Kowa Co Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
JPH0720997B2 (ja) 1988-08-29 1995-03-08 興和株式会社 新規なトロンビン結合性物質及びその製法
JPH02255699A (ja) 1989-03-28 1990-10-16 Asahi Chem Ind Co Ltd 新規血液抗凝固物質及びその製法
CA2065409C (en) 1990-06-27 2002-05-14 Mochida Pharmaceutical Co., Ltd. Anticoagulant polypeptides
JPH05213998A (ja) 1990-08-03 1993-08-24 Asahi Chem Ind Co Ltd 新規なポリペプチド及びこれを有効成分とする 医薬組成物
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
JPH05310787A (ja) 1992-05-01 1993-11-22 Asahi Chem Ind Co Ltd 新規なポリペプチド
JPH06205692A (ja) 1993-01-08 1994-07-26 Asahi Chem Ind Co Ltd 新規な抗ヒトトロンボモジュリンモノクロ−ナル抗体およびその抗体を用いたヒトトロンボモジュリンの高感度測定方法
EP0685994B1 (en) 1993-02-25 2007-03-21 Abbott Laboratories Multipurpose reagent system for rapid lysis of whole blood samples
JP3007785B2 (ja) 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
JPH083065A (ja) 1994-04-20 1996-01-09 Asahi Chem Ind Co Ltd 肝臓障害に対する治療剤
DE69534016T2 (de) 1994-04-20 2006-03-23 Asahi Kasei Pharma Corp. Verwendung von thrombomodulin gegen lebererkrankungen
US5916874A (en) 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
JP2824392B2 (ja) 1994-05-31 1998-11-11 旭化成工業株式会社 トロンビンによるプロテインcの活性化を促進する作用を有するペプチドを含有する培養上澄液
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
CA2213000A1 (en) 1995-03-06 1996-09-12 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US5872108A (en) 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
JP3789147B2 (ja) 1995-04-11 2006-06-21 旭化成ファーマ株式会社 脊髄損傷後の神経障害に対する治療剤
JPH08301783A (ja) 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
EP0743066A3 (en) 1995-05-16 1998-09-30 Mitsui Pharmaceuticals, Inc. Wound-healing agent
JP3931353B2 (ja) 1995-06-30 2007-06-13 持田製薬株式会社 創傷治癒剤
JP3745805B2 (ja) 1995-10-24 2006-02-15 日本ケミカルリサーチ株式会社 トロンボモジュリンの精製方法
JPH101439A (ja) 1996-06-11 1998-01-06 Mochida Pharmaceut Co Ltd 神経変性疾患治療剤
JP4157644B2 (ja) 1998-03-30 2008-10-01 旭化成ファーマ株式会社 高純度可溶性トロンボモジュリンの製造方法
PT1267915E (pt) * 2000-03-28 2005-09-30 Lilly Co Eli Metodos para tratar doencas com proteina c activada
US20020111296A1 (en) 2000-08-31 2002-08-15 Festoff Barry W. Thrombomodulin analogs for use in recovery of spinal cord injury
JP4340540B2 (ja) * 2002-01-18 2009-10-07 旭化成ファーマ株式会社 可溶性トロンボモジュリン高濃度含有製剤
EP2017276B1 (en) * 2003-09-22 2011-01-19 Euro-Celtique S.A. Phenyl-carboxamide compounds useful for treating pain
US20080280774A1 (en) * 2005-02-16 2008-11-13 Wyeth Methods and Systems for Diagnosis, Prognosis and Selection of Treatment of Leukemia
US9394267B2 (en) 2007-07-13 2016-07-19 The Cleveland Clinic Foundation Heterocyclic modulators of cannabinoid receptors
CN101801187B (zh) 2007-07-13 2014-07-23 得克萨斯系统大学评议会 大麻素受体的杂环调节剂
KR20110008166A (ko) * 2008-02-18 2011-01-26 라보라토리오스 델 드라. 에스테브.에스.에이. 화학요법의 결과로 발생하는 신경병적 통증의 치료를 위한 시그마 수용체 리간드에 결합하는 화합물들의 용도
US20110144024A1 (en) * 2008-07-16 2011-06-16 Paion Deutschland Gmbh Prevention and treatment of radiation injury
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前-乳劑調配物及其製造與使用之方法
JP2011178687A (ja) * 2010-02-26 2011-09-15 Kochi Univ 造血細胞移植に伴う疼痛の予防および/または治療剤
US20110287110A1 (en) * 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
JP5924611B2 (ja) 2010-06-16 2016-05-25 国立大学法人高知大学 造血細胞移植に伴う生着症候群の予防及び/又は治療のための医薬
JP2013533286A (ja) * 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
IN2014DN10075A (en:Method) 2012-05-31 2015-08-21 Univ Kinki

Also Published As

Publication number Publication date
US20150148296A1 (en) 2015-05-28
JP6124417B2 (ja) 2017-05-10
CA2875069A1 (en) 2013-12-05
PT2857037T (pt) 2019-07-19
HK1203846A1 (en) 2015-11-06
IL235984B (en) 2019-09-26
RU2014148171A (ru) 2016-07-20
KR101672114B1 (ko) 2016-11-02
US10709767B2 (en) 2020-07-14
IL235984A0 (en) 2015-01-29
AU2013268725A1 (en) 2014-12-18
DK2857037T3 (da) 2019-07-22
EP2857037A1 (en) 2015-04-08
EP2857037A4 (en) 2016-04-06
NZ702242A (en) 2016-03-31
RU2595857C2 (ru) 2016-08-27
CN104394885A (zh) 2015-03-04
EP2857037B1 (en) 2019-06-26
AU2013268725B2 (en) 2017-02-16
KR20150004855A (ko) 2015-01-13
HUE045997T2 (hu) 2020-01-28
JPWO2013179910A1 (ja) 2016-01-18
WO2013179910A1 (ja) 2013-12-05
JP6279788B2 (ja) 2018-02-14
CN104394885B (zh) 2017-06-30
JP2017141268A (ja) 2017-08-17
CA2875069C (en) 2018-01-02
ES2743767T3 (es) 2020-02-20
JP6427284B2 (ja) 2018-11-21
PL2857037T3 (pl) 2019-12-31
MX364934B (es) 2019-03-28
MX2014014505A (es) 2015-06-02
BR112014028852A2 (pt) 2018-04-24
JP2018095652A (ja) 2018-06-21
IN2014DN10075A (en:Method) 2015-08-21

Similar Documents

Publication Publication Date Title
PL2818481T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi złośliwemu
SI2879672T1 (sl) Kombinirana terapija za zdravljenje multiple skleroze
HUE046292T2 (hu) Melanóma kezelése és diagnosztizálása
PT2832366T (pt) Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar
SMT201900024T1 (it) Terapia combinata per il trattamento di cancro
GB201217296D0 (en) Method of treatment and/or prevention
GB201506561D0 (en) Treatment of amblyopia
ZA201408769B (en) Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent.
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
IL238126A0 (en) Compositions for the treatment and prevention of obesity
IL236321A0 (en) Combined treatment for cancer and immunosuppression
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
GB2502133B (en) Treatment or therapeutic apparatus
GB201213968D0 (en) Prevention and treatment of osteoarthritis
HK40095822A (en) Treatment and diagnosis of melanoma
GB2519004B (en) Quinone compounds and their uses for the treatment of cancer
PT2456445E (pt) Agente para o tratamento de condições da pele
GB201208505D0 (en) Treatment of skin condition
IL233495A0 (en) Combination for cancer treatment
GB201222949D0 (en) Combination Treatment of Cancer
GB201222950D0 (en) Combination treatment of cancer
AU2012902296A0 (en) Compositions for Therapy and Methods of Treatment
GB201208048D0 (en) Treatment of digestive disorder
AU2012900670A0 (en) Treatment of seborrhoea